Monoclonal Antibodies in the Treatment of Malignant Lymphomas

  • Bertrand Coiffier
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 610)

Non-Hodgkin's lymphoma is a heterogeneous group of B- and T-cell cancers, with a large variety of patterns of growth, clinical presentations, and responses to treatment. Outcome depends on histological subtype, tumor characteristics, host responses, and treatment. About 90 percent of lymphomas have a B-cell phenotype and for them recent therapeutic progress came from the introduction of monoclonal antibodies (MAb) alone or in combination with chemotherapy (Coiffier 2005; Coiffier 2005; Traulle and Coiffier 2005). The first antigen that has been targeted for therapeutic purpose with success was the CD20 antigen, a transmembrane protein expressed by more than 99 percent of B-cell lymphomas. Rituximab was the first MAb engineered to target the CD20 antigen and first approved MAb for the treatment of lymphoma patients. Through the last 10 years clinical trials with rituximab have confirmed its efficacy in follicular lymphoma, as well as in aggressive lymphomas, and its use has expanded significantly beyond the initial indication of indolent B-cell lymphomas to virtually any CD20-positive lymphoma. In recent years, several other MAb targeting CD20 or other lymphocyte antigens appeared, some of them associated with a toxin or a radioisotope.


Clin Oncol Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Autologous Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alas, S., Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44.PubMedGoogle Scholar
  2. Alas, S., Bonavida, B., Emmanouilides, C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and Rituximab. Anticancer Res. 2000;20:2961–6.PubMedGoogle Scholar
  3. Ardeshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J., MacLennan, K. A., Marcus, R. E., Jelliffe, A., Hudson, G. V., Linch, D. C. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin’s lymphoma: a randomised controlled trial. Lancet. 2003;362:516–22.PubMedCrossRefGoogle Scholar
  4. Belhadj, K., Delfau-Larue, M. H., Elgnaoui, T., Beaujean, F., Beaumont, J. L., Pautas, C., Gaillard, I., Kirova, Y., Allain, A., Gaulard, P., Farcet, J. P., Reyes, F., Haioun, C. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study. Ann Oncol. 2004;15:504–10.PubMedCrossRefGoogle Scholar
  5. Berinstein, N. L., Grillolopez, A. J., White, C. A., Bencebruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., Shen, D. Association of serum rituximab (IDECC2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001.PubMedCrossRefGoogle Scholar
  6. Bienvenu, J., Chvetzoff, R., Salles, G., Balter, C., Tilly, H., Herbrecht, R., Morel, P., Lederlin, P., Solal-Celigny, P., Audhuy, B., Christian, B., Gabarre, J., Casasnovas, O., Marit, G., Sebban, C., Coiffier, B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J. 2001;2:378–84.PubMedCrossRefGoogle Scholar
  7. Blaes, A. H., Peterson, B. A., Bartlett, N., Dunn, D. L., Morrison, V. A. Rituximab therapy is effective for post-transplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104:1661–7.PubMedCrossRefGoogle Scholar
  8. Boettcher, S., Pott, C., Ritgen, M., Hiddemann, W., Unterhalt, M., Kneba, M. Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. In: Blood, editor. ASH 2004; 2004: Blood; 2004. p. 170a.Google Scholar
  9. Bohen, S. P., Troyanskaya, O. G., Alter, O., Warnke, R., Botstein, D., Brown, P. O., Levy, R. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Nat Acad Sci USA. 2003;100:1926–30.PubMedCrossRefGoogle Scholar
  10. Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R., Costagliola, D. Phase II trial of CHOP plus rituximab in patients with HIVassociated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–8.PubMedCrossRefGoogle Scholar
  11. Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., Grillo-Lopez, A. J., Rosenberg, J., Kunkel, L., Flinn, I. W. Rituximab using a thrice-weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–64.PubMedGoogle Scholar
  12. Byrd, J. C., Peterson, B. L., Morrison, V. A., Park, K., Jacobson, R., Hoke, E., Vardiman, J. W., Rai, K., Schiffer, C. A., Larson, R. A. Randomized phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14.PubMedCrossRefGoogle Scholar
  13. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene. Blood. 2002;99:754–8.PubMedCrossRefGoogle Scholar
  14. Cartron, G., Watier, H., Golay, J., Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–42.PubMedCrossRefGoogle Scholar
  15. Cheson, B. D. Radioimmunotherapy of non-Hodgkin’s Lymphomas. Blood. 2003;101:391–8.PubMedCrossRefGoogle Scholar
  16. Coiffier, B. Current strategies for the treatment of diffuse large B-cell lymphoma. Cur Op Hematol. 2005;12:In press.Google Scholar
  17. Coiffier, B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol. 2005;3:484–91.PubMedGoogle Scholar
  18. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van den Neste, E., Salles, G., Gaulard, P., Reyes, F., Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.PubMedCrossRefGoogle Scholar
  19. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A., Solal-Celigny, P. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–6.PubMedCrossRefGoogle Scholar
  20. Conconi, A., Martinelli, G., Thieblemont, C., Ferreri, A. J. M., Devizzi, L., Peccatori, F., Ponzoni, M., Pedrinis, E., Dell’Oro, S., Pruneri, G., Filipazzi, V., Dietrich, P. Y., Gianni, A. M., Coiffier, B., Cavalli, F., Zucca, E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.PubMedCrossRefGoogle Scholar
  21. Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., Grillo-Lopez, A. J. Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. J Clin Oncol. 2005;23:DOI:10.1200/JCO.2004.04.020.Google Scholar
  22. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., Levy, R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–43.PubMedGoogle Scholar
  23. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., Bonavida, B. Chimeric Anti-Cd20 (Idec-C2b8) Monoclonal Antibody Sensitizes a B-Cell Lymphoma Cell Line to Cell Killing By Cytotoxic Drugs. Cancer Bioth Radiopharm. 1997;12:177–86.CrossRefGoogle Scholar
  24. Dillman, R. O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell Lymphoma. Journal of clinical oncology. 2002;20:3545–57.PubMedCrossRefGoogle Scholar
  25. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A. P., Repp, R., Schetelig, J., Seipelt, G., Osterborg, A., Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P. A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H., Osterborg, A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.Google Scholar
  26. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2004;103:2920–4.Google Scholar
  27. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F., Coiffier, B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l¢Adulte. J Clin Oncol. 2005;23:4117–26.PubMedCrossRefGoogle Scholar
  28. Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., Radford, J. A., Bessell, E. M., Souleau, B., Benzohra, A., Lister, T. A. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–24.PubMedGoogle Scholar
  29. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Haenel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Boeck, H. P., Wandt, H., Unterhalt, M., Hiddemann, W. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas -results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2004;104:3064–71.PubMedCrossRefGoogle Scholar
  30. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., Lehmann, T., Hartmann, F., Einsele, H., Hiddemann, W. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;DOI: 10.1182/blood-2006–04–016725.Google Scholar
  31. Foussard, C., Mounier, N., Van Hoof, A., Delwail, V., Casasnovas, O., Deconinck, E., Tilly, H., Fitoussi, O., Gressin, R., Salles, G. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol. 2006;24.Google Scholar
  32. Ghetie, M. A., Bright, H., Vitetta, E. S. Homodimers. but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392–8.PubMedCrossRefGoogle Scholar
  33. Ghetie, M. A., Crank, M., Kufert, S., Pop, I., Vitetta, E. Rituximab, but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P- glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother. 2006;29:536–44.PubMedCrossRefGoogle Scholar
  34. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M. F., Betticher, D. C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D., Cerny, T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–23.PubMedCrossRefGoogle Scholar
  35. Gianni, A. M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Rambaldi, A., Cortelazzo, S., Patti, C., Parvis, G., Benedetti, F., Capria, S., Corradini, P., Tarella, C., Barbui, T. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749–55.PubMedCrossRefGoogle Scholar
  36. Grillo-Lopez, A. J., Hedrick, E., Rashford, M., Benyunes, M. Rituximab: Ongoing and future clinical development. Sem Oncol. 2002;29:105–12.CrossRefGoogle Scholar
  37. Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.PubMedCrossRefGoogle Scholar
  38. Hagberg, H., Gisselbrecht, C. Randomized phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl 4:iv31–2.PubMedCrossRefGoogle Scholar
  39. Hainsworth, J. D., Litchy, S., Barton, J. H., Houston, G. A., Hermann, R. C., Bradof, J. E., Greco, F. A. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746–51.PubMedCrossRefGoogle Scholar
  40. Hainsworth, J. D., Litchy, S., Burris, H. A., Scullin, D. C., Corso, S. W., Yardley, D. A., Morrissey, L., Greco, F. A. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–7.PubMedCrossRefGoogle Scholar
  41. Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., Greco, F. A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–95.PubMedCrossRefGoogle Scholar
  42. Herold, M., et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. In:Blood, editor. ASH; 2004; San Diego: Blood; 2004. p. 169a.Google Scholar
  43. Hiddemann, W., Dreyling, M. H., Forstpointner, R., Kneba, M., Woermann, B., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Schmitz, N., Truemper, L., Eimermacher, H., Parwaresch, R. Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves Time To Treatment Failure in First Line Therapy of Follicular Lymphoma Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). In: Blood, editor. American Society of Hematology; 2003; San Diego, CA: Blood; 2003. p. 104a.Google Scholar
  44. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H. E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R., Unterhalt, M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.PubMedCrossRefGoogle Scholar
  45. Hochster, H. S., Weller, E., Ryan, T., Habermann, T. M., Gascoyne, R., Frankel, S. R., Horning, S. J. Results of E1496: A phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma. In: ASCO P, editor. ASCO; 2004; New Orleans, LA: Proc ASCO; 2004. p. 556.Google Scholar
  46. Horwitz, S. M., Horning, S. J. Rituximab in stem cell transplantation for aggressive lymphoma. Curr Hematol Rep. 2004;3:227–9.PubMedGoogle Scholar
  47. Jain, A. B., Marcos, A., Pokharna, R., Shapiro, R., Fontes, P. A., Marsh, W., Mohanka, R., Fung, J. J. Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center. Transplantation. 2005;80:1692–8.PubMedCrossRefGoogle Scholar
  48. Janas, E., Priest, R., Wilde, J. I., White, J. H., Malhotra, R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139:439–46.PubMedCrossRefGoogle Scholar
  49. Juweid, M. E. Radioimmunotherapy of B-Cell Non-Hodgkin’s lymphoma: From clinical trials to clinical practice. Journal of Nuclear Medecine. 2002;43:1507–29.Google Scholar
  50. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., Wahl, R. L. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9.PubMedCrossRefGoogle Scholar
  51. Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, A. T., Staag, R. J., Tidmarsh, G. F., Kroll, S., Walh, R. L., Knox, S. J., Vose, J. M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. Journal of clinical oncology. 2001;19:3918–28.PubMedGoogle Scholar
  52. Kaplan, L. D., Scadden, D. T. for the AIDS Malignancies Consortium. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIVassociated non-Hodgkin’s lymphoma: AIDS malignancies consortium study 010. In: Oncol PASC, editor. ASCO; 2004: Proc Am Soc Clin Oncol 2004. p. 564.Google Scholar
  53. Keating, M. J., Flinn, I., Jain, V., Binet, J. L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., Rai, K. R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–61.PubMedCrossRefGoogle Scholar
  54. Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M. A., Lynn, A., Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–88.PubMedCrossRefGoogle Scholar
  55. Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., Taylor, R. P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–8.PubMedGoogle Scholar
  56. Kim, D. H., Jung, H. D., Kim, J. G., Lee, J. J., Yang, D. H., Park, Y. H., Do, Y. R., Shin, H. J., Kim, M. K., Hyun, M. S., Sohn, S. K. FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720–5.PubMedCrossRefGoogle Scholar
  57. Kimby, E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.PubMedCrossRefGoogle Scholar
  58. Lemieux, B., Bouafia, F., Thieblemont, C., Hequet, O., Arnaud, P., Tartas, S., Traulle, C., Salles, G., Coiffier, B. Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematol J. 2004;In press.Google Scholar
  59. Lemieux, B., Coiffier, B. Radio-immunotherapy in low-grade non-Hodgkin’s lymphoma Best Practice & Research Clinical Haematology 2005;18:81–95.Google Scholar
  60. Lemieux, B., Tartas, S., Traulle, C., Espinouse, D., Thieblemont, C., Bouafia, F., Alhusein, Q., Antal D., Salles, G., Coiffier, B. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:921–3.PubMedCrossRefGoogle Scholar
  61. Lim, S. H., Zhang, Y., Wang, Z., Esler, W. V., Beggs, D., Pruitt. B., Hancock, P., Townsend, M. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant. 2005;35:207–8.PubMedCrossRefGoogle Scholar
  62. Lim, S. H., Zhang, Y., Wang, Z., Esler, W. V., Beggs, D., Pruitt, B., Hancock, P., Townsend, M. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. 46th meeting of the American Socity of Hematology; 2004; San Diego, CA: Blood; 2004. p. 395a.Google Scholar
  63. Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T., Osterborg, A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267–72.PubMedCrossRefGoogle Scholar
  64. Maloney, D. G. Preclinical and phase I and II trials of rituximab. Sem Oncol. 1999;26:74–8.Google Scholar
  65. Marcus, R., Imrie, K., Belch, A., Cunningham, D, Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A., Smith, P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.PubMedCrossRefGoogle Scholar
  66. Marcus, R., Solal-Celigny, P., Imrie, K., Catalano, J., Dmoszynska, A., Raposo, J., Offner, F., Gomez-Codina, J. MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (NHL). Blood. 2006;108:.Google Scholar
  67. McLaughlin, P., Grillolopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bencebruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., Dallaire, B. K. Rituximab Chimeric Anti-Cd20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma - Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol. 1998;16:2825–33.PubMedGoogle Scholar
  68. Milpied, N., Vasseur, B., Parquet, N., Garnier, J. L., Antoine, C., Quartier, P., Carret, A. S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A. M., Bourquard, P., de Ligny, B. H., Dubief, F., Mathieu-Boue, A., Leblond, V. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol. 2000;11:113–6.PubMedCrossRefGoogle Scholar
  69. Neumann, F., Harmsen, S., Martin, S., Kronenwett, R., Kondakci, M., Aivado, M., Germing, U., Haas, R., Kobbe, G. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol. 2006;85:530–4.PubMedCrossRefGoogle Scholar
  70. O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., Keating, M. J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–70.PubMedGoogle Scholar
  71. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology. 2001;19:376–88.PubMedGoogle Scholar
  72. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P. L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E., Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.PubMedCrossRefGoogle Scholar
  73. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B., Glenn, S., Fisher, D. R., Porter, B., Matthews, D. C., Gooley, T., Bernstein, I. D. Phase II trial of 131I–B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–40.PubMedCrossRefGoogle Scholar
  74. Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., Bush, S. A., Durack, L. D., Martin, P. J., Fisher, D. R., Wood, B., Borrow, J. W., Porter, B., Smith, J. P., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D. A Phase I/II trial of iodine-131-tositumomab (anti CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–42.PubMedGoogle Scholar
  75. Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., Leblanc, M., Gaynor, E. R., Rivkin, S. E., Fisher, R. I. A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin ymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606–12.PubMedCrossRefGoogle Scholar
  76. Rosenblum, M. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma. Adv Pharmacol. 2004;51:209–28.PubMedCrossRefGoogle Scholar
  77. Salles, G., Foussard, C., Mounier, N., Morschhauser, F., Bosly, A., Lamy, T., Haioun, C., Brice, P., Boubadallah, R., Rossi, J-F, Audhuy, B., Fermé, C., Mahe, B., Lederlin, P., Sebban, C., Colombat, P., Xerri, L. Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomized trial. In:Blood, editor. ASH; 2004; San Diego: Blood; 2004. p. 49a.Google Scholar
  78. Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.PubMedCrossRefGoogle Scholar
  79. Traulle, C., Coiffier, B. B. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol. 2005;1:297–306.PubMedCrossRefGoogle Scholar
  80. van Oers, M., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., Veer, Mvt, Vranovsky, A., Holte, H., Glabbeke, Mv., Teodorovic, I., Rozewicz, C., Hagenbeek, A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.PubMedCrossRefGoogle Scholar
  81. Vega, M. I., Huerta-Yepaz, S., Garban, H., Jazirehi, A., Emmanouilides, C., Bonavida, B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530–40.PubMedCrossRefGoogle Scholar
  82. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., Kaminski, M.S. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. Journal of clinical oncology. 2000;18:1316–23.PubMedGoogle Scholar
  83. Weng, W. K., Levy, R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin’s lymphoma. Blood. 2001;98:1352–7.PubMedCrossRefGoogle Scholar
  84. Weng, W. K., Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7.PubMedCrossRefGoogle Scholar
  85. Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K. A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H., Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–8.PubMedCrossRefGoogle Scholar
  86. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217–24.PubMedGoogle Scholar
  87. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., White, C. A. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9.PubMedCrossRefGoogle Scholar
  88. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multany, P., White, C. A. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s Lymphoma. Journal of clinical oncology. 2002;20:2453–63.PubMedCrossRefGoogle Scholar
  89. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., Silverman, D. H., Parker, E., Grillo-Lopez, A. J. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. Journal of clinical oncology. 1999;17.Google Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Bertrand Coiffier
    • 1
  1. 1.Hematology DepartmentHospices Civils de Lyon and Claude Bernard UniversityFrance

Personalised recommendations